Nanjing Hicin Pharmaceutical (300584.SZ) plans to increase the capital of Anqing Huichen by 0.2 billion yuan and introduce 0.125 billion yuan of new investment.

Nanjing Hicin Pharmaceutical (300584.SZ) announced that its wholly-owned subsidiary, Anqing Huichen Technology Co., Ltd. ("Anqing Huichen...

Zhitong FinanceOct 11 03:58 ET

Nanjing Hicin Pharmaceutical (300584.SZ): Wholly-owned subsidiary plans to increase capital and expand shares, The company waives some of its preferential subscription rights.

格隆汇October 11th | nanjing hicin pharmaceutical (300584.SZ) announced that its wholly-owned subsidiary Anqing Huichen plans to increase its capital and expand its shares. The registered capital will be increased from RMB 175 million to RMB 500 million, with an additional registered capital of 325 million, including Gu Yuqin (Chinese citizen) subscribing for an additional capital of RMB 18.5 million in monetary form, Qian Demin (Chinese citizen) subscribing for an additional capital of RMB 16.5 million in monetary form, Lu Shiping (Chinese citizen) subscribing for an additional capital of RMB 15 million in monetary form, and Jiang Jinyuan (Chinese citizen) subscribing for an additional capital of RMB 7,50.

Gelonghui FinanceOct 11 03:47 ET

Nanjing Hicin Pharmaceutical's (SZSE:300584) Three-year Earnings Growth Trails the Notable Shareholder Returns

Simply Wall StOct 4 18:58 ET

There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.

New variant appears.

Gelonghui FinanceAug 26 23:33 ET

Nanjing Hicin Pharmaceutical: Half-year report for the year 2024.

SZSIAug 22 12:00 ET · Announcements

Nanjing Hicin Pharmaceutical: Summary of Half-Year Report in 2024.

SZSIAug 22 12:00 ET · Announcements